CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Dyne extends slide as J.P. Morgan downgrades on Novartis setback

negativeNegative
AI Analysis

Summary

J.P. Morgan downgraded Dyne Therapeutics following a setback related to its partnership with Novartis. The analyst action contributed to continued decline in Dyne's stock price.

Outcome Details

Novartis setback

Importance:4/10
Sentiment:
-0.70
downgradepartnershipstock_decline
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on September 9, 2026 1:20 PM

Read Original